Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.

Renal failure - 1 Jan 2012

Hu Ching-Chih, Weng Cheng-Hao, Lin Chih-Lang, Tien Hui-Ching, Kuo Yen-Lin, Chien Cheng-Hung, Yen Cho-Li, Lin Chun-Yen, Chien Rong-Nan

Abstract excerpt

BACKGROUND: Combination therapy with pegylated interferon (pegIFN)-α and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection is associated with reduction in hemoglobin (Hb) concentrations and anemia. The aim of this study was to evaluate the magnitude and frequency of change in Hb and determine the predictive risk factors for Hb decrease during this therapy. METHODS: We enrolled 308 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemoglobins

Share to Injections, Subcutaneous

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 22264026
DOI: 10.3109/0886022X.2011.650562

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.PMID 22264026Read ↗

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.Semantic proximity Read ↗

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.Semantic proximity Read ↗

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.Semantic proximity Read ↗

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.Semantic proximity Read ↗

Pharmacogenetics of ribavirin-induced anemia in HCV patients.Semantic proximity Read ↗

Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.Semantic proximity Read ↗

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.Semantic proximity Read ↗

Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.Semantic proximity Read ↗

Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.Semantic proximity Read ↗

Factors influencing ribavirin-induced hemolysis.Semantic proximity Read ↗

Ribavirin in the treatment of chronic hepatitis C.Semantic proximity Read ↗

High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.